Florida International University
Edit Your Profile
FIU Discovery
Toggle navigation
Browse
Home
People
Organizations
Scholarly & Creative Works
Research Facilities
Support
Edit Your Profile
JOURNAL OF CLINICAL ONCOLOGY
Journal
Overview
Research
Identifiers
Other
View All
Overview
publication venue for
A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR).
. 42:tps2089-tps2089.
2024
A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).
. 42:tps2093-tps2093.
2024
Biomarker development from functional precision medicine datasets via explainable machine learning.
. 42:10061-10061.
2024
Clinical utility and accessibility of functional precision medicine for relapsed/refractory pediatric and adult cancers.
. 42:1551-1551.
2024
Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003.
. 42:12011-12011.
2024
Racial/ethnic distribution of participants in NRG oncology clinical trials: 2014-2023.
. 42:e13706-e13706.
2024
Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.
. 42:2008-2008.
2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma
. 42.
2024
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
. 41:5189-+.
2023
Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide compared to standard cytology.
. 41:2028-2028.
2023
Prophylactic cranial irradiation in small cell lung cancer patients in the era of magnetic resonance imaging: A systematic review and meta-analysis.
. 41:e20636-e20636.
2023
RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade gliomas in adults.
. 41:2017-2017.
2023
Genome-Wide Association Study Identifies
ROBO2
as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors
. 41:1758-+.
2023
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
. 41:1285-+.
2023
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
. 40:2539-+.
2022
A prospective multidisciplinary review of radiotherapy processes during the telemedicine era.
. 39:282-282.
2021
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update
. 39:2037-+.
2021
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient
. 38:3773-+.
2020
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
. 38.
2020
A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101).
. 38:12007-12007.
2020
Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.
. 38:3617-3617.
2020
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
. 38:2563-2563.
2020
Hospitalization for complications due to systemic therapy in the United States.
. 38:7078-7078.
2020
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.
. 38:2518-2518.
2020
Radiofrequency ablation versus stereotactic body radiotherapy for painful osseous metastases: A comparative correlation meta-analysis of pain relief.
. 38:e24156-e24156.
2020
Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).
. 38:2501-2501.
2020
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
. 38:3615-3615.
2020
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
. 38:1019-+.
2020
Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards
. 38:633-+.
2020
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
. 37:3152-+.
2019
A prospective blinded study of 1000 cases analyzing the role of artificial intelligence: Watson for oncology and change in decision making of a Multidisciplinary Tumor Board (MDT) from a tertiary care cancer center.
. 37:6533-6533.
2019
NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer.
. 37:tps8578-tps8578.
2019
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
. 37:453-+.
2019
Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?
. 36:3277-+.
2018
Concordance, decision impact and guidelines adherence using artificial intelligence in high-risk breast cancer.
. 36:e18566-e18566.
2018
Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.
. 36:tps3108-tps3108.
2018
UGT2B17 deletion polymorphism and exemestane-induced toxicity.
. 36:e12534-e12534.
2018
Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.
. 35:8527-8527.
2017
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline
. 35:361-+.
2017
Clinical and pathological characterization of patients (pts) with functional deficiency of the fanconi anemia (FA) pathway.
. 34:e23247-e23247.
2016
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227
. 34:1620-U142.
2016
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
. 34:731-+.
2016
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
. 34:611-+.
2016
An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC).
. 33:e16586-e16586.
2015
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial
. 32:3810-U198.
2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer
. 32:2735-2743.
2014
Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a
BRCA1
or
BRCA2
Mutation
. 32:1547-U43.
2014
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of
IDH
. 32:783-+.
2014
Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02
. 32:535-+.
2014
Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non-Small-Cell Lung Cancer
. 31:4343-U67.
2013
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
. 31:4085-+.
2013
Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline
. 31:2942-+.
2013
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
. 31:lba2010-lba2010.
2013
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
. 31:1-1.
2013
A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424.
. 31:2008-2008.
2013
Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay.
. 31:e16525-e16525.
2013
Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825.
. 31:2003-2003.
2013
Does aggressive primary debulking surgery influence survival in ovarian cancer?
. 31:5561-5561.
2013
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
. 31:lba2010-lba2010.
2013
Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.
. 31:2004-2004.
2013
Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results.
. 31:2033-2033.
2013
Prognostic factors and outcome of atypical and anaplastic meningioma with and without radiation.
. 31:2083-2083.
2013
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
. 31:1-1.
2013
RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
. 31:2047-2047.
2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase ii trial
. 31:1415-1421.
2013
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
. 31:337-343.
2013
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
. 30:3065-3070.
2012
Social Influences on Clinical Outcomes of Patients With Ovarian Cancer
. 30:2885-2890.
2012
Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study
. 30:2648-2653.
2012
A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles.
. 30:2001-2001.
2012
Cervical cancer treatment for operable lesions in a low-resource contemporary setting.
. 30:5107-5107.
2012
Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study.
. 30:2008b-2008b.
2012
Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases.
. 30:2013-2013.
2012
The effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: Secondary analysis of RTOG 98-02.
. 30:2047-2047.
2012
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
. 30:1553-1561.
2012
Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non-Small-Cell Lung Cancer: The ECOG 3598 Study
. 30:616-622.
2012
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
. 30:419-425.
2012
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
. 29:2689-2695.
2011
RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma.
. 29:lba2000-lba2000.
2011
RTOG 0525: Molecular correlates from randomized phase III trial of newly diagnosed glioblastoma (GBM).
. 29:lba2000-lba2000.
2011
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer
. 29:1140-1145.
2011
Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder.
. 29:257-257.
2011
Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors.
. 28:tps168-tps168.
2010
The Impact of the Privacy Rule on Cancer Research: Variations in Attitudes and Application of Regulatory Standards
. 27:4014-4020.
2009
A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598
. 27:7503-7503.
2009
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402
. 27:e20519-e20519.
2009
MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma
. 27:2051-2051.
2009
Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
. 27:5512-5512.
2009
RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)
. 27:2011-2011.
2009
What is the optimal strategy to confirm the diagnosis of epithelial ovarian carcinoma (EOC) prior to neoadjuvant chemotherapy (NAC)?
. 27:5511-5511.
2009
Correlation of O
6
-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
. 26:4189-4199.
2008
Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells
. 26:14637-14637.
2008
Acute radiation esophagitis in a phase I dose-escalation trial evaluating helical tomotherapy for inoperable non-small cell lung cancer (NSCLC)
. 25:7694-7694.
2007
Identification of occult brain metastases amenable to stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment planning MRI: Results of a phase II trial of MGd and whole brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS)
. 25:2037-2037.
2007
Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non- small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials
. 25:2010-2010.
2007
Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701
. 25:2017-2017.
2007
Oxaliplatin plus paclitaxel for recurrent and metastatic cervical cancer (CC): New York Cancer Consortium Trial P5840
. 25:5549-5549.
2007
Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)
. 25:lba5529-lba5529.
2007
Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function
. 25:1260-1266.
2007
Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model
. 24:5711-5715.
2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
. 24:5025-5033.
2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study
. 24:3651-3656.
2006
An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma
. 24:1527-1527.
2006
Daily set up variation in patients receiving radiation with tomotherapy for lung tumors
. 24:17005-17005.
2006
Feasibility report of stereotactic body radiotherapy with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation
. 24:17097-17097.
2006
Improvement in neurocognitive function (NCF) correlates with tumor regression after whole brain radiation therapy (WBRT) for brain metastases (BM)
. 24:1504-1504.
2006
Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG)
. 24:1500-1500.
2006
Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial
. 24:7014-7014.
2006
Phase I study of concurrent motexafin gadolinium (MGd) with radiation therapy for children with newly diagnosed brain stem gliomas (BSG): A Children’s Oncology Group study
. 24:9014-9014.
2006
Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04–20
. 24:1510-1510.
2006
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
. 24:2707-2714.
2006
Prospective neurocognitive effects and quality of life (QOL) in patients with multiple brain metastases receiving whole brain radiation (WBRT) ± thalidomide on radiation therapy oncology group (RTOG) trial 0118
. 24:8589-8589.
2006
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival
. 24:1517-1517.
2006
Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer
. 24:5076-5076.
2006
Tumor volume changes on serial imaging with megavoltage CT for non-small cell lung cancer during conformal radiotherapy
. 24:17041-17041.
2006
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: An eastern cooperative oncology group study (E 6397)
. 23:8870-8876.
2005
Problems in colon cancer and a child with renal lymphoma: Case 2. Metastatic colon cancer to the testicle presenting as testicular hydrocele
. 23:5256-5257.
2005
Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting
. 23:7188-7198.
2005
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American brain tumor consortium study
. 23:6647-6656.
2005
Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients
. 23:5088-5093.
2005
A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boosts for supratentorial glioblastoma multiforme. RTOG-0023
. 23:1511-1511.
2005
An autologous tumor-derived heat shock protein vaccine for high risk ovarian cancer
. 23:9592-9592.
2005
Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas
. 23:4027-4027.
2005
Phase III study of the eastern cooperative oncology group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer
. 23:3760-3767.
2005
RTOG 0118: A phase III study of conventional radiation therapy alone vs. conventional radiation therapy plus thalidomide for multiple brain metastases
. 23:1500-1500.
2005
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas
. 23:1520-1520.
2005
Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer
. 23:5052-5052.
2005
Validation of blinded events review committee (ERC)-determined time to neurologic progression (TTNP) demonstrates correlation with survival, radiologic progression, and functional independence endpoints
. 23:1534-1534.
2005
Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer
. 22:2800-2807.
2004
Phase II study of Fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American brain tumor consortium study
. 22:4282-4289.
2004
A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021
. 22:1529-1529.
2004
A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021
. 22:1529-1529.
2004
An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+ radiation for newly-diagnosed glioblastoma (GBM) patients
. 22:1571-1571.
2004
An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+ radiation for newly-diagnosed glioblastoma (GBM) patients
. 22:1571-1571.
2004
Evaluation of expression of DNA repair molecules as a prognostic factor for long-term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosoureas
. 22:1509-1509.
2004
Evaluation of expression of DNA repair molecules as a prognostic factor for long-term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosoureas
. 22:1509-1509.
2004
Is neoadjuvant chemotherapy a realistic alternative to primary surgery for women with advanced ovarian cancer?
. 22:5043-5043.
2004
Is neoadjuvant chemotherapy a realistic alternative to primary surgery for women with advanced ovarian cancer?
. 22:5043-5043.
2004
Long term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosurea have higher initial expression of Ki-67
. 22:9661-9661.
2004
Long term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosurea have higher initial expression of Ki-67
. 22:9661-9661.
2004
Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group Study (E6397)
. 22:1507-1507.
2004
Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group Study (E6397)
. 22:1507-1507.
2004
Toxicities associated with chemotherapy followed by craniospinal radiation for adults with poor-risk medulloblastoma/PNET and disseminated ependymoma; a preliminary report of ECOG 4397
. 22:1573-1573.
2004
Toxicities associated with chemotherapy followed by craniospinal radiation for adults with poor-risk medulloblastoma/PNET and disseminated ependymoma; a preliminary report of ECOG 4397
. 22:1573-1573.
2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: Phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group
. 22:120-126.
2004
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial
. 22:157-165.
2004
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
. 21:2529-2536.
2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium study
. 21:2305-2311.
2003
RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database
. 21:2364-2371.
2003
Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394
. 21:1485-1491.
2003
Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases
. 19:2074-2083.
2001
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer
. 17:2922-2931.
1999
Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy
. 17:2553-2561.
1999
Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American brain tumor consortium report
. 17:984-990.
1999
Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American brain tumor consortium report
. 16:2188-2194.
1998
Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial
. 15:2850-2857.
1997
Critical role of phase I clinical trials in cancer treatment
. 15:853-859.
1997
Phase II study of paclitaxel in patients with recurrent malignant glioma
. 14:2316-2321.
1996
Funding for clinical (patient-oriented) oncology research: Current status and recommendations for improvement
. 14:666-670.
1996
CLINICAL IMPACT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN PATIENTS WITH GYNECOLOGIC CANCER
. 12:2317-2320.
1994
PILOT TRIAL OF CISPLATIN, RADIATION, AND WR2721 IN CARCINOMA OF THE UTERINE CERVIX - A NEW-YORK GYNECOLOGIC-ONCOLOGY-GROUP STUDY
. 11:1511-1516.
1993
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy
. 11:1517-1522.
1993
PHASE-II STUDY AND LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH TAXOL FOR ADVANCED OVARIAN ADENOCARCINOMA
. 10:1748-1753.
1992
PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THIOTEPA ADMINISTERED INTRAPERITONEALLY IN PATIENTS WITH ADVANCED MALIGNANCIES
. 7:132-139.
1989
Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide compared to standard cytology
2023
Prophylactic cranial irradiation in small cell lung cancer patients in the era of magnetic resonance imaging: A systematic review and meta-analysis
2023
RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade gliomas in adults
2023
Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (RMPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).
2020
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
2020
Associations of caregiver-oncologist discordance in prognostic understanding with caregiver-reported therapeutic alliance and anxiety.
2019
Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM).
2019
Barriers to accrual and enrollment in brain tumor trials.
2019
Insight into the brain metastasis journey: Initial survey results from patients and caregivers.
2019
NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer.
2019
Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.
2019
Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).
2019
Gender and preferences for palliative care: Perceptions of efficacy.
2018
Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.
2018
The MD CaREs initiative: Tailoring oncology education to ethnically and culturally diverse students.
2018
METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC
2017
Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT plus PCV in high-risk low-grade gliomas (LGGs).
2016
Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT plus TMZ vs RT plus nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).
2016
Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402.
2016
Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC)
2015
Phase II study of arsenic trioxide and temozolomide ut combination with radiation therapy in patients with malignant gliomas
2014
TOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancer-A collaborative study of RTOG and KROG (NCT01622868)
2014
Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
2013
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
2013
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
2013
A phase II study of a temozolomide-based chemoradiotherapy regimen for high-rish low-grade gliomas: Preliminary results of RTOG 0424
2013
Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay.
2013
Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825
2013
Does aggressive primary debulking surgery influence survival in ovarian cancer?
2013
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
2013
Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825
2013
Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiaiton temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results
2013
Prognostic factors and outcome of atypical and anaplastic meningioma with and without radiation
2013
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
2013
RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
2013
A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles
2012
Cervical cancer treatment for operable lesions in a low-resource contemporary setting.
2012
Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study
2012
Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases
2012
Phase I/II study of Y-90-clivatuzumab tetraxetan (Y-90-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results.
2012
The effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: Secondary analysis of RTOG 98-02.
2012
RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma
2011
RTOG 0525: Molecular correlates from randomized phase III trial of newly diagnosed glioblastoma (GBM).
2011
Variation over time and interdependence between disease progression and death among patients with glioblastoma (GBM) on RTOG 0525.
2011
Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC)
2011
Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials.
2010
Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): The role of a new chemotherapy (CT) induced apoptosis assay
2010
Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond
2010
Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC)
2010
A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598
2009
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402
2009
MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma
2009
Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
2009
RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)
2009
What is the optimal strategy to confirm the diagnosis of epithelial ovarian carcinoma (EOC) prior to neoadjuvant chemotherapy (NAC)?
2009
Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database
2009
Phase II trial of twice daily oral topotecan in combination with hyperfractionated radiotherapy for limited stage small cell lung carcinoma
2008
Acute radiation esophagitis in a phase I dose-escalation trial evaluating helical tomotherapy for inoperable non-small cell lung cancer (NSCLC)
2007
Identification of occult brain metastases amenable to stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment planning MRI: Results of a phase II trial of MGd and whole brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS)
2007
Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials
2007
Outcome for metastatic (M plus ) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701
2007
Oxaliplatin plus paclitaxel for recurrent and metastatic cervical cancer (CC): New York Cancer Consortium Trial P5840
2007
An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastorna.
2006
Improvement in neurocognitive function (NCF) correlates with tumor regression after whole brain radiation therapy (WBRT) for brain metastalses (BM).
2006
Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG).
2006
Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial.
2006
Phase I study of concurrent motexafin gadolinium (MGd) with radiation therapy for children with newly diagnosed brain stem gliomas (BSG): A Children's Oncology Group study.
2006
Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04-20.
2006
Prospective neurocognitive effects and quality of life (QOL) in patients with multiple brain metastases receiving whole brain radiation (WBRT) +/- thalidomide on radiation therapy oncology group (RTOG) trial 0118.
2006
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliornas and mixed anaplastic oligodendrogliomas: Relationship between lp/19q status and progression-free survival.
2006
A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boosts for supratentorial glioblastoma multiforme. RT0G-0023
2005
RTOG 0118: A phase III study of conventional radiation therapy alone vs. conventional radiation therapy plus thalidomide for multiple brain metastases.
2005
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas
2005
Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer.
2005
Validation of blinded events review committee (ERC)-determined time to neurologic progression (TTNP) demonstrates correlation with survival, radiologic progression, and functional independence endpoints
2005
A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-00211.
2004
An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib plus radiation for newly-diagnosed glioblastoma (GBM) patients.
2004
Evaluation of expression of DNA repair molecules as a prognostic factor for long-term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosoureas.
2004
Is neoadjuvant chemotherapy a realistic alternative to primary surgery for women with advanced ovarian cancer?
2004
Long term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosurea have higher initial expression of Ki-67.
2004
Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group Study (E6397).
2004
Toxicities associated with chemotherapy followed by craniospinal radiation for adults with poor-risk medulloblastoma/PNET and disseminated ependymoma; a preliminary report of ECOG 4397.
2004
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points
2002
Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593
1998
Immunochemotherapy, the New Standard of Care for Primary CNS Lymphoma: However, Which One? Reply
2016
Valproate in Adjuvant Glioblastoma Treatment Reply
2016
Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
2016
Reply to MC Chamberlain
2015
Lessons Learned From Radiation Therapy Oncology Group 0525 Trial Reply
2014
Is Graded Prognostic Assessment an Improvement Compared With Radiation Therapy Oncology Group's Recursive Partitioning Analysis Classification for Brain Metastases? Reply
2012
Primary CNS lymphomas prognosis - In reply
2007
Avoiding bias in the prospective evaluation of patients with brain metastases - In reply
2007
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer [10]
2005
Association of tamoxifen and uterine sarcoma
2002
Dimension in defining tumor response
1998
Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era
2024
Medical Education and Training: Building In-Country Capacity at All Levels
2016
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
2009
Whole-brain radiotherapy in the management of brain metastasis
2006
Current management of brain metastases, with a focus on systemic options
2005
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
2021
Digital measurement of functional status of patients with glioblastoma.
2021
Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.
2021
Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas.
2021
The brain metastasis journey: Experience from patient, caregiver, and physician surveys on diagnosis and treatment of brain metastases.
2021
Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer: Untapped clinical utility and PARP inhibitor trial eligibility.
2019
NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).
2019
Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.
2019
Phase 2 trial of durvalumab and radiation revaccination in patients with metastatic adenocarcinoma of the pancreas who have progressed through first-line chemotherapy.
2019
Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology's RTOG 0614.
2018
Impact of prophylactic bilateral salpingo-oophorectomy on bone health in BRCA mutation carriers: A prospective cohort study
2018
Integrated clinical experience with ONC201 in H3 K27M glioma.
2018
Intratumoral activity of ONC201 in adult recurrent glioblastoma patients
2018
NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.
2018
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.
2016
Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non-Small-Cell Lung Cancer (vol 31, pg 4343, 2013)
2016
Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer
2015
Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA)
2015
Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG
2014
The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers.
2014
It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology
2011
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
2011
The Dandelion Effect: Treat the Whole Lawn or Weed Selectively?
2011
Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT+ procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG)
2008
Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601
2008
Models support prophylactic cranial irradiation
2006
Increasing access to clinical cancer trials and emerging technologies for minority populations: The Native American project
2004
Gynecologic surveillance of women on tamoxifen: First do no harm
2000
Research
category
ONCOLOGY
Category
Identifiers
International Standard Serial Number (ISSN)
0732-183X
Electronic International Standard Serial Number (EISSN)
1527-7755
Other
journal abbreviation
J CLIN ONCOL